Which dose of bevacizumab is more effective for the treatment of aggressive posterior retinopathy of prematurity: lower or higher dose?

Basit Öğe Kaydı
dc.contributor.authorDikci, Seyhan
dc.contributor.authorCeylan, Osman Melih
dc.contributor.authorDemirel, Soner
dc.contributor.authorYılmaz, Turgut
dc.date.accessioned2019-07-29T11:50:58Z
dc.date.available2019-07-29T11:50:58Z
dc.date.issued2018
dc.departmentİnönü Üniversitesien_US
dc.description.abstractPurpose: To compare 0.5 mg and 0.625 mg of bevacizumab for treating aggressive posterior retinopathy of prematurity (AP-ROP). Methods: The medical records of patients with AP-ROP who were administered intravitreal bevacizumab (IVB) as a primary treatment at a university clinic were evaluated retrospectively. Five eyes of three patients (Group 1) who received 0.625 mg/0.025 ml IVB and 10 eyes of another five patients (Group 2) who received 0.5 mg/0.02 ml IVB were evaluated. Laser photocoagulation was used as additional treatment after relapses. Anatomic results and complications were evaluated in both groups. Results: We evaluated 15 eyes of eight patients (four girls and four boys) with a flat demarcation line at posterior zone 2 and plus disease or stage-3 disease in this study. The mean gestational age of the three babies in Group 1 was 26 +/- 1 weeks and the mean birth weight was 835.33 +/- 48.01 g. The corresponding values were 25.2 +/- 1.6 weeks and 724 +/- 139.03 g, respectively, for the five babies in Group 2. Retinal vascularization was completed at a mean postmenstrual duration of 53.6 +/- 1.5 weeks without additional treatment in the five eyes in Group 1. Laser photocoagulation for relapse was administered to five of the 10 eyes in Group 2. Retinal vascularization was completed at a mean postmenstrual duration of 47.6 +/- 1.5 weeks in the remaining five eyes. None of the patients developed complications such as cataract, glaucoma, retinal tear, retinal or vitreous hemorrhage, or retinal detachment. Conclusion: Although lower IVB doses in the treatment of AP-ROP are expected to be safer in terms of local and systemic side effects in premature infants, these patients may require additional treatment with IVB or laser photocoagulation.en_US
dc.identifier.citationDikici, S. Ceylan, OM. Demirel, S. Yılmaz, T. (2018). Which dose of bevacizumab is more effective for the treatment of aggressive posterior retinopathy of prematurity: lower or higher dose?. Cilt:81 Sayı:1, 12-17 ss.en_US
dc.identifier.doi10.5935/0004-2749.20180005en_US
dc.identifier.endpage17en_US
dc.identifier.issue1en_US
dc.identifier.startpage12en_US
dc.identifier.urihttps://hdl.handle.net/11616/13048
dc.identifier.volume81en_US
dc.language.isoenen_US
dc.publisherConsel brasıl oftalmologıa, alameda santos 1343, 11 andar cj 1110, cerqueıra cesar, sao paulo, sp 00000, brazılen_US
dc.relation.ispartofArquıvos brasıleıros de oftalmologıaen_US
dc.rightsinfo:eu-repo/semantics/restrictedAccessen_US
dc.subjectEndothelıal Growth-Factoren_US
dc.subjectZone-I Retınopathyen_US
dc.subjectIntravıtreal Bevacızumaben_US
dc.subjectLaser Photocoagulatıonen_US
dc.subjectInjectıonen_US
dc.subjectPharmacokınetıcsen_US
dc.subjectRanıbızumaben_US
dc.subjectAvastınen_US
dc.subjectRısken_US
dc.titleWhich dose of bevacizumab is more effective for the treatment of aggressive posterior retinopathy of prematurity: lower or higher dose?en_US
dc.typeArticleen_US

Dosyalar

Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.71 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Tıp Fakültesi, Göz Hastalıkları Anabilim Dalı Koleksiyonu